Late onset haemorrhagic cystitis (HC) occurs in 20-30% of allogeneic bone marrow transplant patients. Human polyomavirus BK (BKV) (or less frequently adenovirus) may be involved in the pathogenesis of viral HC and can represent a serious post-transplant complication. Diagnosis and treatment of viral HC can be difficult and has an uncertain outcome. We report the efficacy of sequential vidarabine in the treatment of a patient with severe BKV-associated HC, despite the delay in implementing therapy. Bone Marrow Transplantation (2000) 25, 319-320. Keywords: BK virus; haemorrhagic cystitis; sequential vidarabine infusion Late-onset haemorrhagic cystitis (HC) occurs in 20-30% of bone marrow transplant (BMT) patients.
Late-onset haemorrhagic cystitis (HC) occurs in 20-30% of bone marrow transplant (BMT) patients. 1, 2 A strong association has been observed between HC and reactivation of the human polyomavirus BK, with viral shedding in the urine. 2, 3 Less frequently, involvement of adenovirus infection in HC has also been reported. 4 However, urinary shedding of BKV and of adenoviruses (among others) may frequently be asymptomatic. Urinary shedding of BKV or of adenovirus may be demonstrated by the Papanicolau stain allowing detection of inclusion bodies and by transmission electron microscopy (TEM) allowing observation of viral particles in the urinary sediments, 5 as well as by virus isolation in cell cultures. However, the use of DNA hybridisation assays with labeled probes and especially of PCR has greatly improved the diagnosis of such infections. 2, 3 Among the therapeutic approaches that have been adopted against viral HC, vidarabine has been reported to be active against double-stranded DNA viruses including human BKV. 6 Here, we describe the successful use of vidarabine in the treatment of a BKV patient with severe haemorrhagic cystitis. 
Case report
A 48-year-old man with acute myeloid leukaemia (FAB M6) in complete remission received an allogeneic BMT from his HLA-identical brother. Conditioning was with busulphan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) plus cyclophosphamide 50 mg/kg once daily i.v. on days 5-8 (total dose 200 mg/kg). Prophylaxis of acute acrolein-induced haemorrhagic cystitis was with continuous infusion of mesna and hyperhydratation. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporin and a short course of methotrexate. Bone marrow transplant was carried out without significant complications. Marrow engraftment occurred at day +18 posttransplant. The patient was discharged on day +35 after BMT, with no transfusion requirement.
On day +60 he was re-admitted with severe diarrhoea. Cytomegalovirus (CMV) antigenemia was concomitantly detected (47 cells). As routine faecal cultures for bacteria, fungi and viruses were negative, the diarrhoea was thought to be related to GVHD. High doses of steroids and gancyclovir at a dose of 5 mg/kg twice daily i.v. together with total parenteral nutrition (TPN) led to improvement in the clinical situation and an improvement in the CMV antigenemia (0-2 cells). On day +66, the patient started to experience frank haematuria without fever. Parenteral antibiotics, continuous bladder irrigation and bladder instillation of prostaglandin E1 at a dose of 500 g once daily for 7 days were started. Nevertheless, the symptoms progressed to moderate and gross haematuria including clots. His full blood count revealed severe anemia (haemoglobin decreasing to 4 g/dl despite red blood cell transfusions) with platelets 15 × 10 9 /l and white cell count 4.4 × 10 9 /l. Urine cultures for bacteria, fungi and viruses were negative as was examination of urinary sediment by TEM. The patients's clinical condition progressively deteriorated with severe abdominal colicky-type pain. Presence of acute obstructive renal failure with bilateral hydronephrosis was demonstrated on ultrasound examination and cystoscopy was subsequently performed. The urothelium showed a macroscopic picture of bullave and necrotic inflammation. The urethra was freed of clots, and bladder biopsies were performed during cystoscopy. Immunohistochemical examination for CMV and TEM for polyomavirus were negative.
A ureteric stent was sited for 1 week leading to an improvement of the renal picture. The HC showed a fluctuating clinical course, with phases of partial remission and relapse even though the platelet count was maintained at Ͼ30 × 10 9 /l. Further laboratory investigations of urine specimens, using PCR for BKV and adenovirus DNA detection as already described, 2 were positive for BKV DNA and negative for adenovirus DNA. On day +174, treatment with vidarabine was started at the dosage of 10 mg/kg once daily i.v. for 5 days, given as 12 h infusions. Treatment was well tolerated and symptoms and haematuria improved after 1 week, before worsening again after 3 weeks. Vidarabine was thus repeated for two more cycles, with a slight temporary increase in transaminases. The patient subsequently remained in a good clinical condition and no more red blood cell transfusions were necessary, although the urinary PCR assay remained positive.
On day +218 he again worsened and experienced fever. A chest X-ray revealed interstitial pneumonia, and his mental status deteriorated. CMV antigenemia was again strongly positive with no signs of cystitis. The patient died on day +225 from respiratory failure.
Discussion
In contrast to the early-onset HC that frequently follows BMT, and can usually be attributed to cyclophosphamidecontaining regimens and occurs within 48 h of infusion despite 2-mercaptoethane (mesna) prophylaxis, late-onset HC is generally associated with viral infections. The first viruses to be detected in late-onset HC were adenoviruses, which were found after paediatric BMTs, as well as after kidney transplants and in immune-deficient patients. 6, 7 However, in recent years BKV has emerged as the main cause of late-onset HC, probably because of the improved sensitivity of the methods used for its detection. 2 However, the high sensitivity of PCR-based techniques may overestimate the importance of the virus as a causative agent, because BKV DNA found in the urine could originate in the blood where it is known that polyomavirus is frequently present. BKV has also occasionally been associated with hepatitis and interstitial pneumonia following BMT. 8, 9 In our patient, urinary symptoms appeared late (on day +66), and although viral infection was suspected, TEM of the urinary sediment was negative for BKV, adenovirus and other viruses. The CMV antigenemia which was initially detected disappeared after gancyclovir treatment, whereas only a slight, transient improvement in the HC was observed. It was the use of nested PCR that allowed detection of BKV in the urine during an HC episode and prompted us to use vidarabine. Although the interval between diagnosis and treatment has been reported to play an important negative role in the outcome of vidarabine therapy of BKV-associated HC, 5 our patient responded well to sequential treatment. Three cycles of therapy with vidarabine were well tolerated and led to progressive improvement in signs and symptoms associated with HC, even though the treatment had been started rather late with respect to the onset of cystitis. Urinary detection of BKV several days after recovery from HC has previously been reported after both vidarabine (and prostaglandin E 2 ) treatment. 10 It is possible that in the absence of the support of the immune system, which is initially compromised in BMT patients, vidarabine is only capable of reducing viral replication and tissue damage, without completely clearing the virus.
Although it is impossible to demonstrate with certainty that vidarabine was the single reason for the improvement because HC often has a waxing and waning course, a striking time relationship between starting vidarabine and the remarkable clinical improvement makes this association very likely. We conclude that a PCR assay for BKV should be performed in immune deficient patients with HC, and specific treatment with vidarabine seems to be justified when BKV is detected in symptomatic patients, particularly in view of negligible toxicity. Sequential infusion of the drug may be well tolerated and useful even after a delay in diagnosis.
